Practices: Intellectual Property | Licensing | Patent Litigation | Litigation and Dispute Resolution | Appellate | Pharmaceutical, Biotechnology and Medical Device Industries | Healthcare & Life Sciences
CharlesA.Weiss is a partner in Holland & Knight's New York office and head of the New York Intellectual Property Group. He concentrates his practice on technology-driven litigation, counseling and transactions, primarily in the pharmaceutical, chemical and biotechnology areas. He also counsels clients on questions of patent validity and infringement, and provides a litigator's perspective on prosecution matters.
Mr. Weiss litigates patent, trade secret, license and false advertising cases in diverse technical areas. He has handled cases over the years involving expression of recombinant proteins and antibodies, controlled release pharmaceuticals, medical diagnostic agents, endocrine and hormone products, nutritional supplements, industrial control systems, food chemistry, nucleic acid diagnostic assays and commercial detergents. He also has extensive experience in the investigation of product counterfeiting and pursuit of those responsible.
In addition, Mr. Weiss has a diverse non-litigation practice, focused on supporting transactions in which a substantial value is attributed to a party's patent position, such as its ability to exclude competitors or to bring its product to market free of meritorious infringement claims by others. He has negotiated and drafted licenses and other agreements, including commercial collaboration, joint research and product acquisition agreements, and regularly advises financial professionals on the strength or vulnerability of a target company's patent positions.
Mr. Weiss also has experience in commercial matters, including corporate and securities transactions, contract litigation, insurance and banking disputes, construction litigation, accounting and attorney malpractice, and investigations of employee malfeasance and fraud. Mr. Weiss is an adjunct professor at New York Law School, where he designed a course on patent litigation and analysis, and is also an associate adjunct professor at Brooklyn Law School, where he designed and teaches a course on food and drug law.
Honors & Awards
The Best Lawyers in America guide, Patent Law, 2013, 2014
IAM Patent Litigation 250, International Asset Management magazine, 2011-2014
Tau Beta Pi
Eta Kappa Nu
American Bar Association, Section of Litigation; Section of Intellectual Property Law; Business Law Section
New York State Bar Association, Intellectual Property Law Section; Commercial and Federal Litigation Section
New York Intellectual Property Law Association, Amicus Briefs Committee
Federal Circuit Bar Association
Institute of Electrical and Electronics Engineers
IP, Patents and Trademarks, Danish Life Sciences Investor Forum, October 1, 2013
Columbia University Law School, J.D.
Washington University, BSEE, Electrical Engineering, Physics minor, cum laude
U.S. Patent and Trademark Office
U.S. Court of Appeals for the Federal Circuit
U.S. Court of Appeals for the Second Circuit
U.S. Court of Appeals for the Third Circuit
U.S. Supreme Court
Christopher Tobin is a partner in Michael Best’s Intellectual Property Practice Group. Mr. Tobin’s practice focuses on patent prosecution and counseling, with an emphasis on high technology intellectual property matters.
Mr. Tobin has significant experience in patent preparation, prosecution, litigation and examination, as well as in post-grant procedures such as reexamination, Inter Partes Review and supplemental examination. He has also assisted clients with intellectual property portfolio management and assessment in relation to planned acquisition, due diligence related to portfolio acquisition and auditing of existing patent portfolios.
Mr. Tobin has experience with a wide variety of technologies related to the electrical and computer arts, including networks, display and imaging devices, electronic commerce, semiconductors, electrical circuitry and software.
Prior Work Experience
Mr. Tobin has previously worked as a patent examiner and senior patent counsel for a multinational corporation.
Member, American Intellectual Property Law Association
Member, Institute of Electrical and Electronics Engineers
Honors and Recognitions
Named Client Service All-Star by BTI Consulting Group, Inc. (2016)
IAM Patent 1000 (2014, 2015)
Little League Baseball Coach (2003-2009)
Youth Development League Basketball Coach (2004-2012)
Eric Huang is a partner in Quinn Emanuel's New York office. He represents both plaintiffs and defendants in intellectual property matters. He specializes in building patent infringement cases on either side of the “v” in highly technical subject matter. He has extensive experience litigating patent cases involving a wide range of technologies – smartphones, user interface software, touchscreen technology, circuits, semiconductor processing, spreading and modulation techniques used in wireless communication, various aspects of 3G and 4G cellular communications, error control coding including turbocodes and low density parity check codes, digital video compression, audio compression, pharmaceutical formulations, fiber optics, liquid crystal displays, mechanical measurement devices, electronic engine control, e-commerce, and computer systems.
His practice encompasses all aspects of case preparation, pre-trial discovery, expert preparation, trial preparation and trial in U.S. federal district courts and before the U.S. International Trade Commission. He served as a trial counsel for respondent Samsung in ITC investigation 337-TA-796 initiated by Apple against Samsung's smartphones, tablets and media players. The firm successfully defended against efforts to stop the importation of Samsung devices; to date, no Samsung device was excluded or seized as a result of any order from this investigation. Eric recently helped secure a very favorable jury verdict for Marvell Semiconductor in a case brought by France Telecom in San Francisco federal district court alleging infringement by Marvell’s 3G baseband chips. In addition to a favorable damages verdict of a fraction of the damages sought by plaintiff, the firm recently secured judgment for Marvell Semiconductor on post-trial motions in that case. Eric also has experience prosecuting patents and is admitted to the U.S. Patent & Trademark Office.
Eric’s representative clients include BlackBerry, California Institute of Technology, Canon, Marvell Semiconductor, MediaTek, Monolithic Power Systems, Motorola, Reliant Pharmaceuticals, Rovi, Samsung, and Sony.
Prior to joining Quinn Emanuel, Eric was an associate with the law firm of Fish & Neave and served as a law clerk to the Honorable Eric Bruggink on the U.S. Court of Federal Claims (1997-1998). He is a 1997 graduate of the George Washington University Law School, and has a materials science & engineering degree from the University of Michigan in Ann Arbor. Prior to law school, Eric worked for National Semiconductor in California as an electronic packaging engineer. He currently serves on the Board of Directors of the New York Lawyers for the Public Interest and the Board of Trustees for the Blue School, a private independent school in New York City.
John Hintz is a partner in the Intellectual Property Litigation Practice Group in the New York office of Rimon, P.C. He has more than twenty-seven years of experience in intellectual property matters, particularly patent litigation.
Mr. Hintz has worked on all aspects of patent disputes and has litigated in federal courts throughout the country and before the International Trade Commission. He also has significant transactional, licensing, and counseling experience, including advising clients on the IP aspects of IPOs, mergers and acquisitions, and the transfer and licensing of IP assets.
Mr. Hintz provided expert testimony about U.S. patent law in patent-related proceedings between Samsung and Apple in five countries, and he has represented clients in a wide range of industries covering diverse technologies such as semiconductors, search engines, financial services, barcode scanning, ecommerce, telecommunications, computer simulations, commodity chemicals, polymers, process control instruments, medical devices, and life sciences.
Mr. Hintz has received numerous awards and recognition from his peers and legal publications including being named by Best Lawyers as “Lawyer of the Year” in the category “Litigation-Patent, New York City Area” in 2013.
Marta Gross, a senior partner in Goodwin Procter’s IP Litigation Group, is a member of its Patent Litigation and Life Sciences Practices. She also serves on the firm’s Executive Committee.
For more than 25 years, Ms. Gross has focused her practice on patent matters, including patent litigation, strategic counseling and opinions, and patent-related due diligence. She has been recognized as one of the country’s leading IP lawyers by a number of industry publications, including LMG Life Sciences, Managing Intellectual Property and Super Lawyers.
Work for Clients
Ms. Gross developed the strategic patent counseling practice to support Teva, the world’s largest generic pharmaceutical company. For more than 10 years she has led this practice team, which provides validity and infringement advice and opinions, as well as strategic counseling, to numerous life science clients.
Lead counsel for Roxane Laboratories (Roxane) in a patent infringement action filed by Prometheus under the Hatch-Waxman Act in response to Roxane’s filing of an abbreviated new drug application (ANDA) for the pharmaceutical drug alosetron. After a bench trial, the District Court found Prometheus’s patent invalid.
Lead counsel for Makhteshim Agan of North America (MANA) and Control Solutions (CSI) in a patent infringement action brought in North Carolina by BASF and Bayer on three patents relating to the pesticide fipronil. The district court granted MANA’s and CSI’s motion for summary judgment of no infringement, which was affirmed by the Federal Circuit. Ms. Gross’s clients were able to launch the first generic fipronil termiticide.
Lead counsel for Roxane in a patent infringement action filed by Genzyme under the Hatch-Waxman Act in response to Roxane’s filing of an ANDA for the pharmaceutical drug doxercalciferol. After trial and while on appeal, the case successfully settled and Roxane was permitted to launch its product prior to the expiration of the asserted patent.
Lead counsel for Roxane in a patent infringement action filed by Sepracor (now Sunovion) under the Hatch-Waxman Act in response to Roxane’s filing of an ANDA for the pharmaceutical drug eszopiclone. The case successfully settled.
Lead counsel for Roxane in a patent infringement action filed by Novartis under the Hatch-Waxman Act in response to Roxane’s filing of an ANDA for the pharmaceutical drug oxcarbazepine. Roxane launched its product prior to the expiration of the asserted patent and subsequently the case successfully settled.
Counsel for Cytec in an infringement action filed by Ciba in the District of Delaware on patents involving polymeric microbead technology. The case was resolved by summary judgment in favor of Cytec.
Ms. Gross has represented numerous additional clients in major patent litigations including:
Exxon in a high profile action brought by Dow on patents relating to polyolefin catalyst technology
Becton Dickinson in a patent litigation brought by Critikon on patents involving safety catheter technology
Hoechst Roussel in a patent litigation brought by Warner Lambert on a patent for a drug for treating Alzheimer’s disease
Dade-Behring in a patent litigation brought against Biosite on a patent involving methods and devices for performing immunoassays
AlliedSignal in a patent litigation brought by FilmTec on a patent involving reverse osmosis technology
Ms. Gross is a member of the New York City Bar Association and served a three-year term as chair of its Patents Committee. She is also a member of the ABA, AIPLA and NYIPLA and has served on various committees of those organizations.
Ms. Gross has lectured on intellectual property law matters such as legal issues for startups, pharmaceutical patents and litigation and patent basics. She has participated in and chaired programs presented at organizations including MIT, Practising Law Institute and the University of Toronto.
Ms. Gross worked as an engineer (including having major managerial responsibilities) for eight years after her graduation from MIT, during the latter portion of which she attended evening law school. She gained from her engineering experience real-world perspectives regarding the kinds of problems her corporate clients face and finding practical solutions to those problems.
Ms. Gross first worked at General Electric where she participated in GE’s Manufacturing Management Program. Thereafter, she worked at Millipore Corporation. At Millipore, She was the Manager of New Product Development. In that role, she managed the group responsible for bringing Millipore’s new chemical-related chromatography products from the research and development stage to full scale manufacture, in accordance with a schedule and a budget.
In 2014, Ms. Gross was named a “Life Sciences Star” in the LMG Life Science Survey; was named an IP Star and one of Managing Intellectual Property magazine’s “Top 250 Women in IP”; and was named one of the leading attorneys in New York by the publication Super Lawyers. She has also been named to the 2014 Women in Business Law Expert Guide.
J.D., Suffolk University School of Law, 1988 (Evening Division, cum laude)
Sc.B., Chemical Engineering, Massachusetts Institute of Technology, 1980
Bar and Court Admissions
Ms. Gross is admitted to practice in New York and Massachusetts, as well as before the U.S. Patent & Trademark Office and various federal courts.
Sarah A. Solomon is a partner in the firm’s Technology & Life Sciences Group.
Ms. Solomon represents biotechnology, pharmaceutical, medical device, diagnostic and other life sciences companies in connection with their intellectual property, commercial and M&A transactions. She regularly advises private and public companies on complex strategic collaboration and partnering transactions (such as co-development, joint research and development agreements, patent licenses, strategic alliances and joint ventures); research, development and commercial relationships (such as manufacturing, distribution, supply, clinical trial, university licenses and services arrangements); and mergers and acquisitions (such as product acquisitions, spin-outs and patent portfolio acquisitions). Ms. Solomon also counsels clients in connection with international transactions and relationships in North America, South America, Europe and Asia.
J.D., University of California Hastings College Law, 2001
B.S., Biology, University of California, San Diego, 1996
Bar and Court Admissions
Ms. Solomon is admitted to practice in California.
Jane works with a wide range of biotechnology and pharmaceutical clients on strategic portfolio development and management, world-wide patent prosecution, opinions, search-based analyses including freedom to operate advice, USPTO interferences, foreign oppositions and IP diligence.
Jane provides advanced strategic advice to her clients, on patent matters in technologies including genomics, vaccines, transgenic animals, assays and high throughput genomics and proteomics systems, discovery genetics, diagnostics, personalized medicine, gene silencing and diverse biologics. Jane has over 15 years of experience obtaining world-wide protection for antibodies.
Representative Clients and Matters
Jane represented Amgen (and previously we represented Abgenix) on a patent portfolio relating to the XENOMOUSE® technology, one of the most significant developments in the last quarter century in making available therapeutic antibodies for human therapy
Jane represents Eisai in intellectual property matters, including opinions, counseling, search-based analyses and patent prosecution
Honors & Awards
PLC Which Lawyer (2010-2011)
Memberships & Affiliations
American Bar Association
American Intellectual Property Law Association
New York State Bar Association
Presentations & Speeches
"Securing Patents for Antibodies Against a Backdrop of Heightened Patentability Requirements," 18th Forum On Biotech Patenting, Munich (March 2010)
"Securing Patents for Antibodies Against a Backdrop of Heightened Patentability Requirements," 17th Forum On Biotech Patenting, London (October 2009)
"Maximizing Patent Term Under 35 U.S.C. § 154," 7th Annual MAXIMIZING PHARMACEUTICAL PATENT LIFE CYCLES, Brand Name Master Class, New York (October 2009)
"Breaking Through the Challenges Associated with Antibody Patent Prosecution," 11th Advanced Forum On Biotech Patents, Boston (October 2009)
"The Narrowing Scope of Biotech Patent Claims: What Does It Mean for the Industry?" BIO International Conference, Atlanta (May 2009)
"Issues in Biotechnology Patenting: Are Prosecutors and Litigators on the Same Page and Can They Get There?" New York Biotechnology Association 18th Annual Meeting (April 2009)
"Maximizing Patent Term Under 35 U.S.C. § 154," 7th Annual MAXIMIZING PHARMACEUTICAL PATENT LIFE CYCLES, Brand Name Master Class, New York (October 2007)
"Maximizing Patent Term Under 35 U.S.C. § 154," 7th Annual MAXIMIZING PHARMACEUTICAL PATENT LIFE CYCLES, Brand Name Master Class, San Francisco (June 2007)
"Antibody Patentability," Advanced Forum On Biotech Patents, C5 Conference, Munich (April 2007)
"Patent Portfolio Management," Pharmaceutical/Biotech Industry Forum, New York (February 2007)
"Maximizing Patent Term Under 35 U.S.C. § 154," 7th Annual MAXIMIZING PHARMACEUTICAL PATENT LIFE CYCLES, Brand Name Master Class, New York (October 2006)
"Antibody Patentability," Advanced Forum On Biotech Patents, C5 Conference, London (September 2006)
"Maximizing Patent Term Under 35 U.S.C. § 154," 6th Annual MAXIMIZING PHARMACEUTICAL PATENT LIFE CYCLES, Brand Name Master Class, New York (October 2005)
"Antibody Patentability," 5th Advanced Forum on Biotech Patents, American Conference Institute, New York (September 2005)
"Integra v. Merck Safe Harbor Provisions," Advanced Forum On Biotech Patents, American Conference Institute, New York (January 2005)
"Patent Prosecution Basics," Patent Basics for the Non-Specialist, Practicing Law Institute (2005-present)
"Antibody Patentability," 4th Advanced Forum on Biotech Patents, American Conference Institute (December 2004)
"A Tactical And Practical Guide To FREEDOM TO OPERATE," American Conference Institute, New York (November 2003)
"PTO GUIDELINES FOR EXAMINATION UNDER § 102(e) IN VIEW OF AMERICAN INVENTORS PROTECTION ACT," Joint Patent Practice Seminar Connecticut, New Jersey, New York and Philadelphia Intellectual Property Law Associations, New York (May 2003)
"FOCUS ON RESEARCH TOOLS/METHOD PATENTS," Advanced Forum On Biotech Patents, American Conference Institute, New York and San Francisco (April and October 2003) (April 2004)
"CAN A PATENT APPLICATION HAVE TOO MUCH DISCLOSURE?" New York Biotechnology Association (February 2003)
"How to Protect Your Databases of Genomic and Proteomic Data: The US Perspective," EuroLegal Conference: Patenting your Genomic and Proteomic Inventions, London (July 2002)
JD, Columbia University School of Law, Harlan Fiske Stone Scholar
MS (Biology), New York University
BA (Cell Biology), Smith College, with Honors
New York U.S. Patent and Trademark Office
Supreme Court of the United States, 2005 U.S. Court of Appeals for the Federal Circuit, 2001 U.S. District Court for the Southern District of New York, 1994 U.S. District Court for the Eastern District of New York, 1994